<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01045889</url>
  </required_header>
  <id_info>
    <org_study_id>ema2_LNH e HIV</org_study_id>
    <nct_id>NCT01045889</nct_id>
  </id_info>
  <brief_title>High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk</brief_title>
  <acronym>HDT-HIV</acronym>
  <official_title>First Line Treatment in HIV-related Large Cell Non Hodgkin Lymphoma at &quot;High Risk&quot;, Including Early Consolidation With High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Spedali Civili di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Spedali Civili di Brescia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy of an intensified first-line treatment,
      with conventional chemotherapy (CHOP) plus monoclonal antibody anti CD20, followed by high
      dose chemotherapy and PBSC transplantation in HIV-related aggressive non-Hodgkin lymphoma at
      &quot;high risk&quot; , according to the international prognostic index (IPI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV associated NHL show particularly aggressive clinical features and a worse prognosis
      compared to the general population. The recent introduction of highly active antiretroviral
      therapy (HAART)has improved HIV positive patients' clinical conditions and reduced the risk
      of opportunistic infections, thus making HIV+ patients more similar to HIV- patients. Several
      studies have shown that the early use (as first line treatment) of high dose chemotherapy
      (HDT) with peripheral blood stem cell transplantation (PBSCT) is superior in the HIV negative
      setting to conventional dose chemotherapy, at least in patients with poor prognostic factors
      at diagnosis. Recently, several experiences have shown the feasibility, safety and efficacy
      of HDT and PBSCT, in association with HAART, as salvage therapy in HIV positive patients with
      lymphoma who maintain a chemosensitive disease after first-line treatment failure. It is
      rationale therefore to explore the use of this treatment strategy earlier, within the upfront
      treatment of HIV-associated lymphoma, in those patients with poor prognostic factors at
      diagnosis, according to the international prognostic score (IPI).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2-years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial and complete responses</measure>
    <time_frame>Evaluation of response one month after peripheral blood transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>HIV-related Lymphoma</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>R-CHOP + PBSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive chemoimmunotherapy with Rituximab + CHOP regimen for 6 cycles followed by high dose cyclophosphamide and stem cell collection, then high dose therapy with BEAM conditioning regimen and peripheral blood stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rituximab and CHOP regimen + PBSCT</intervention_name>
    <arm_group_label>R-CHOP + PBSCT</arm_group_label>
    <other_name>Mabthera</other_name>
    <other_name>cyclophosphamide</other_name>
    <other_name>adryamicin</other_name>
    <other_name>vincristine</other_name>
    <other_name>prednisone</other_name>
    <other_name>BiCNU</other_name>
    <other_name>etoposide</other_name>
    <other_name>aracytin</other_name>
    <other_name>melphalan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positivity

          -  &quot;Large cell&quot;histology (DLBCL, Immunoblastic, Plasmablastic, Anaplastic lymphoma)

          -  Age 18-60 years

          -  Age-adjusted IPI 2-3

          -  Ann Arbor stage I B-IV

          -  Written informed consent.

        Exclusion Criteria:

          -  Burkitt lymphoma

          -  Lymphoblastic lymphoma

          -  Primary effusion lymphoma

          -  Age-adjusted IPI 0-1

          -  Performance Status (WHO) &gt;2 (if not related to lymphoma)

          -  Inadequate cardiac function (V.E.F. &lt; 50%) or clinically evident cardiac disease

          -  Inadequate pulmonary function (DLCO &lt; 50% and/or O2 &lt; 96%)

          -  Inadequate renal function (creatinine &gt; 2 mg/dl)

          -  Inadequate liver function (AST/ALT &gt; 3 ULN and/or PT &lt; 70%, if not related to
             lymphoma)

          -  Inadequate marrow function (neutrophils &lt; 1500/cmm; platelets &lt; 100.000/cmm, if not
             related to lymphoma)

          -  Virologic failure to HAART (including at least one NRTI, one NNRTI and two PI) and/or
             CD4 count &lt; 50/cmm.

          -  CNS or meningeal lymphoma

          -  Active opportunistic infections

          -  Pregnancy

          -  Other evolutive malignancy (except of localized non-melanoma skin cancer and in situ
             portio carcinoma)

          -  Any other condition that contraindicates this treatment program at discretion of
             physician

          -  HBsAg positivity with active viral replication (HBV-DNA positivity)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Rossi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haematology Division - AO Spedali Civili di Brescia - Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AO Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M, Spina M, Manuele R, Vaccher E, Mazzucato M, Abbruzzese L, Ferremi P, Carosi G, Tirelli U, Rossi G. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009 Aug 13;114(7):1306-13. doi: 10.1182/blood-2009-02-202762. Epub 2009 May 18.</citation>
    <PMID>19451551</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Spedali Civili di Brescia</investigator_affiliation>
    <investigator_full_name>Giuseppe Rossi</investigator_full_name>
    <investigator_title>Director of Hematology</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>non hodgkin lymphoma</keyword>
  <keyword>peripheral blood stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, AIDS-Related</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

